Investor Overview Announcements Date Title 2021/05/31 The company has acquired ordinary shares of Obigen Pharma, Inc. 2021/05/13 OBI-999 completes its Phase 1 safety evaluation and demonstrates its safety with no major concerns, proceeding to Phase 2 as planned Read More Annual Report 2019Annual Report (PDF) 2018Annual Report (PDF) See More Financial Report 2020Financial Report Q1 2019Financial Report Q1 See More Stock Quote See More Event Calendar See More Monthly Revenues See More Corporate GovernanceRead More StakeholderRead More Company Profile Read More
